|

MB-CART2019.1 Clinical Trials

3 actively recruiting trials

▲ +1 trial since May 2026

Also known as: Anti-CD20/CD19 CAR T cells, CD20/CD19-targeting CAR T cells

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Miltenyi Biomedicine GmbH3

Indications

  • CAR T Cell Therapy2
  • Cancer2
  • Chronic Lymphatic Leukemia1
  • Childhood Non-Hodgkin Lymphoma1
  • Acute Lymphatic Leukemia1

Other3 trials

DALY II Japan/MB-CART2019.1 for DLBCL
Phase 2
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
N/A
MB-CART2019.1 in Refractory Multiple Sclerosis
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.